Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease

Respiratory Research

Volumn 13, Issue 1, 2012, Pages

  Celli, Bartolome R ^a   Decramer, Marc ^b   Lystig, Theodore ^c   Kesten, Steven ^c   Tashkin, Donald P ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COPD; Inspiratory Capacity; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUCOLYTIC AGENT; OXYGEN; PLACEBO; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX;

EID: 84864525399     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-66     Document Type: Article

References (26)

1. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. National Heart, Lung and Blood Institute, Bethesda; 2001. http://www.goldcopd.org
2. O'Donnell DE, Webb KA: Exertional breathlessness in patients with chronic airflow limitation. The role of hyperinflation. Am Rev Resp Dis 1993, 148:1351-1357.
3. O'Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:1557-1565.
4. O'Donnell DE, Revill SM, Webb KA: Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:770-777.
5. Casanova C, Cote C, de Torres JP, Aquirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory capacity-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2005, 171:591-597.
6. Fletcher C, Peto R: The natural history of chronic airflow obstruction. Br Med J 1977, 1:1645-1648.
7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J Am Med Assoc 1994, 272:1497-1505.
8. The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 2000, 343:1902-1909.
9. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999, 340:1948-1953.
10. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000, 320:1297-1303.
11. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005, 365:1552-1560.
12. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhard D, Cassino C, Kesten S: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT® trial. J COPD 2004, 1:303-312.
13. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: for the UPLIFT® Investigators: A 4-year trial of tiotropium in patients with chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
14. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
15. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
16. American Thoracic Society: Standardization of spirometry, 1994 update Am J Respir Crit Care Med 1995, 152:1107-1136.
17. O'Donnell D, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
18. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guérin JC, Le Merre C, Iacono P, Huchon G: The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006, 73:420-427.
19. National Emphysema Treatment Trial Research Group: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema N Engl J Med 2003, 348:2059-2073.
20. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D: Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest 2005, 128:1168-1178.
21. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94.
22. Kohansal R, Matinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009, 180:3-10.
23. Celli B, ZuWallack R, Wang S, Kesten S: Improvements in resting inspiratory capacity and hyperinflation with tiotropium in COPD with increased static lung volumes. Chest 2003, 124:1743-1748.
24. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP: UPLIFT Study Investigators: Mortality in the 4-year trial of tiotropium (UPLIFT®) in patients with COPD. Am J Respir Crit Care Med 2009, 180:948-955.
25. Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Diaz H, Celli BR, Pinto-plata VM: Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 2008, 32:1275-1282.
26. Calverley P, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 2007, 356:775-789.